IDEAYA Biosciences, Inc 8-K, filed Nov 3, 2026
IDEAYA Biosciences, Inc. (IDYA)
About this 8-K
IDEAYA Biosciences, Inc filed this 8-K on November 3, 2026.
IDEAYA Biosciences completed its darovasertib NDA submission, stopped enrollment in OptimUM-010 to save $100-125 million, and reported a $125.7 million net loss with $1.15 billion in cash and marketable securities at September 30, 2026. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IDEAYA BIOSCIENCES, INC. |
|
|
|
Date: November 3, 2026 |
By: |
/s/ Yujiro Hata |
|
|
Yujiro Hata |
|
|
Chairman and Chief Executive Officer |
Exhibit 99.1
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma,” said Yujiro S. Hata, Chief Executive Officer of IDEAYA. “We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC. Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech.”
Selected Pipeline Developments and Corporate Updates
Darovasertib for Uveal Melanoma (UM)
Exhibit 99.1
Antibody-drug conjugates (ADCs)
Exhibit 99.1
MTAP pathway
Exhibit 99.1
KAT6/7
Corporate
Third Quarter 2026 Financial Results
As of September 30, 2026, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.15 billion, compared to $1.24 billion as of June 30, 2026. The decrease was
Exhibit 99.1
primarily driven by net cash used in operations. IDEAYA’s cash runway guidance into 2030 is unchanged based on the current operating plan.
Collaboration revenue for the three months ended September 30, 2026, totaled $10.2 million, compared to $8.9 million for the three months ended June 30, 2026. Collaboration revenue was recognized for the performance obligations satisfied through September 30, 2026 related to the research and development services that are recognized over time under the Servier exclusive license agreement for darovasertib. As of September 30, 2026, the remaining balance for the research and development services performance obligations is $139.8 million related to the clinical development cost reimbursements anticipated under the license agreement that will be recognized as IDEAYA collaboration revenue over time as the research and development services are completed.
Research and development (R&D) expenses for the three months ended September 30, 2026 totaled $121.6 million, compared to $108.7 million for the three months ended June 30, 2026. The increase was primarily driven by higher clinical trial and development costs and personnel-related expenses to support IDEAYA’s programs.
General and administrative (G&A) expenses for the three months ended September 30, 2026 totaled $26.3 million, compared to $22.5 million for the three months ended June 30, 2026. The increase was primarily due to higher personnel-related expenses to support company growth and darovasertib commercial preparation activities.
The net loss for the three months ended September 30, 2026, was $125.7 million compared to the net loss of $112.5 million for the three months ended June 30, 2026. Total stock-based compensation expense for the three months ended September 30, 2026, was $17.7 million compared to $16.7 million for the three months ended June 30, 2026.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
Exhibit 99.1
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding darovasertib’s development and potential clinical benefits, alone and in combination with crizotinib; the interpretation and potential implications of results from OptimUM-01, OptimUM-02 and OptimUM-09; the timing, conduct and outcome of the FDA’s review of the NDA for the darovasertib combination in metastatic uveal melanoma, including under the RTOR program, and the potential approval and commercialization of darovasertib; the design, enrollment, timing and potential results of OptimUM-011; the closure of OptimUM-010, the anticipated cost savings therefrom, and the reallocation of such resources to other programs; the timing of initial clinical data from the global Phase 1/2 trial of IDE849, the planned initiation, design, and endpoints of Phase 3 registrational trials of IDE849, and the potential of IDE849 in SCLC and NEC; the development, timing of data and potential of IDE161, IDE034, IDE892, IDE397 and IDE574, including planned combination cohorts, expansions and trial initiations; IDEAYA’s clinical collaborations; IDEAYA’s cash runway and the sufficiency of its cash, cash equivalents and marketable securities to fund its operating plan; the possibility of establishing a new standard of care; potential effects on eye preservation and visual outcomes; and future clinical studies and data presentations. These statements reflect current expectations and involve risks and uncertainties, and actual results may differ materially from those expressed or implied. Clinical findings may change with additional follow-up, and early results, small cohorts and subgroup analyses may not predict outcomes in larger or subsequent studies. Factors that could cause actual results to differ include, among others, risks related to drug development, regulatory review and approval, clinical trial site activation and enrollment, manufacturing, reliance on collaborations, commercialization, the sufficiency of IDEAYA’s capital resources, changes in IDEAYA’s operating plan and macroeconomic conditions. Additional information about risks is available in IDEAYA’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and its other filings with the Securities and Exchange Commission. IDEAYA does not undertake to update these statements, except as required by law.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
September 30, 2026 |
|
|
June 30, 2026 |
|
|
September 30, 2026 |
|
|
September 30, 2025 |
|
||||
|
|
(Unaudited) |
|
|
(Unaudited) |
|
||||||||||
Collaboration revenue |
|
$ |
10,242 |
|
|
$ |
8,857 |
|
|
$ |
25,660 |
|
|
$ |
207,834 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
121,576 |
|
|
|
108,689 |
|
|
|
325,991 |
|
|
|
228,105 |
|
General and administrative |
|
|
26,298 |
|
|
|
22,459 |
|
|
|
68,135 |
|
|
|
44,472 |
|
Total operating expenses |
|
|
147,874 |
|
|
|
131,148 |
|
|
|
394,126 |
|
|
|
272,577 |
|
Loss from operations |
|
|
(137,632 |
) |
|
|
(122,291 |
) |
|
|
(368,466 |
) |
|
|
(64,743 |
) |
Interest income and other income, net |
|
|
11,883 |
|
|
|
9,839 |
|
|
|
31,726 |
|
|
|
34,318 |
|
Net loss |
|
|
(125,749 |
) |
|
|
(112,452 |
) |
|
|
(336,740 |
) |
|
|
(30,425 |
) |
Unrealized (losses) gains on marketable securities |
|
|
(3,214 |
) |
|
|
(1,176 |
) |
|
|
(7,151 |
) |
|
|
1,240 |
|
Comprehensive loss |
|
$ |
(128,963 |
) |
|
$ |
(113,628 |
) |
|
$ |
(343,891 |
) |
|
$ |
(29,185 |
) |
Net loss per share |
|
$ |
(1.22 |
) |
|
$ |
(1.22 |
) |
|
$ |
(3.56 |
) |
|
$ |
(0.34 |
) |
Weighted-average number of shares |
|
|
102,944,175 |
|
|
|
92,061,452 |
|
|
|
94,620,638 |
|
|
|
88,452,395 |
|
Net loss per share |
|
$ |
(1.22 |
) |
|
$ |
(1.22 |
) |
|
$ |
(3.56 |
) |
|
$ |
(0.34 |
) |
Weighted-average number of shares |
|
|
102,944,175 |
|
|
|
92,061,452 |
|
|
|
94,620,638 |
|
|
|
88,452,395 |
|
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Balance Sheet Data
(in thousands)
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(Unaudited) |
|
|||||
Cash and cash equivalents and short-term and long-term marketable securities |
|
$ |
1,150,827 |
|
|
$ |
1,049,685 |
|
Total assets |
|
|
1,216,020 |
|
|
|
1,109,324 |
|
Total liabilities |
|
|
123,957 |
|
|
|
86,390 |
|
Total liabilities and stockholders' equity |
|
$ |
1,216,020 |
|
|
$ |
1,109,324 |
|